IGC Pharma, Inc. (LS:A1T87A) Financings

IGC Pharma, Inc.

Financings

RaiseDate
Registered direct offering of shares of common stock
Announced: about US$234,000 · US$0.3 a share
Use of proceeds: Working capital and general corporate purposes, including continued funding of the Phase 2 clinical program for IGC-AD1
Jan 5, 2026
Private placements and at-the-market offering
Closed: US$3.5M raised
Aug 19, 2025
Private placement of common shares
Announced: about US$475,000
Buyers: Frank Zaccanelli; Robert K. Coughlin; Joseph H. Mangan
Use of proceeds: General corporate purposes and advancing the CALMA Phase 2 clinical trial on agitation in Alzheimer's disease
Apr 24, 2025

Read by 6ix AI from the company's releases